The Safety, Tolerability and Pharmacokinetic Study of ZSP1273 in Healthy Volunteers.

NCT ID: NCT03679143

Last Updated: 2019-08-14

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 103 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-09-20
• Study Completion Date: 2019-04-26

Brief Summary

This is a single center,double-blind,randomized,parallel design, single and multiple dose trial to evaluate the pharmacokinetics(PK), safety and tolerability of ZSP1273,and the effect of food on ZSP1273 Pharmacokinetics.

Detailed Description

The study will be divided in 3 parts :

Study Part I(Single Ascending Dosing, SAD) will be a single ascending dose to be run at a maximum of 6 dose levels. Subjects included in this part of the study will receive only one dose level to limit the exposure to ZSP1273. Four subjects are planned to be included in the first group while 10 subjects are enrolled in every following cohort.

Study Part II(Multiple Ascending Dosing, MAD) will start after completion of some Cohorts of Study Part I. Study Part II will be a multiple ascending dose to be run at a maximum of 3 dose levels. Subjects included in this part of the study will receive only one dose level. This part also enrolls 10 subjects in every cohort.

Study Part III(Food Effect study, FE) will consists of 2 periods,and subjects will receive a single dose ranged from 100-600mg on fasting and postprandial states respectively. There will be a 7-day wash out period between treatment periods.A total of 12 to 18 subjects will be included.

All the 3 parts will be run in healthy subjects.

Conditions

Influenza

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

ZSP1273(single dose)-100 mg(Cohort 1)

ZSP1273 100 mg /Placebo

Group Type: EXPERIMENTAL

ZSP1273 100 mg

Intervention Type: DRUG

ZSP1273 tablet administered orally once daily under fasted condition

Placebo 100 mg

Intervention Type: DRUG

Participants will receive placebo matching to ZSP1273 orally once daily in the fasting state.

ZSP1273(single dose)-200 mg(Cohort 2)

ZSP1273 200mg/Placebo

Enrollment into Cohort 2 will begin upon assurance of tolerance for Cohort 1.

Group Type: EXPERIMENTAL

ZSP1273 200 mg

Intervention Type: DRUG

ZSP1273 tablets administered orally once daily under fasted condition

Placebo 200 mg

Intervention Type: DRUG

Participants will receive placebo matching to ZSP1273 orally once daily under fasted condition

ZSP1273(single dose)-400 mg(Cohort 3)

ZSP1273 400mg/Placebo

Enrollment into Cohort 3 will begin upon assurance of tolerance for Cohort 2.

Group Type: EXPERIMENTAL

ZSP1273 400 mg

Intervention Type: DRUG

ZSP1273 tablets administered orally once daily in the fasting state

Placebo 400 mg

Intervention Type: DRUG

Participants will receive placebo matching to ZSP1273 orally once daily in the fasting state

ZSP1273(single dose)-600 mg(Cohort 4)

ZSP1273 600 mg/Placebo

Enrollment into Cohort 4 will begin upon assurance of tolerance for Cohort 3.

Group Type: EXPERIMENTAL

ZSP1273 600 mg

Intervention Type: DRUG

ZSP1273 tablets administered orally once daily under fasted condition

Placebo 600 mg

Intervention Type: DRUG

Participants will receive placebo matching to ZSP1273 orally once daily under fasted condition

ZSP1273(single dose)-900 mg(Cohort 5)

Drug:ZSP1273 900 mg/Placebo 900mg；

Enrollment into Cohort 5 will begin upon assurance of tolerance for Cohort 4.

Group Type: EXPERIMENTAL

ZSP1273 900 mg

Intervention Type: DRUG

ZSP1273 tablets administered orally once daily in the fasting state

Placebo 900 mg

Intervention Type: DRUG

Participants will receive placebo matching to ZSP1273 orally once daily under fasted condition

ZSP1273(single dose)-1200 mg(Cohort 6)

ZSP1273 1200 mg/Placebo

Enrollment into Cohort 6 will begin upon assurance of tolerance for Cohort 5.

Group Type: EXPERIMENTAL

ZSP1273 1200 mg

Intervention Type: DRUG

ZSP1273 tablets administered orally once daily in the fasting state

Placebo 1200 mg

Intervention Type: DRUG

Participants will receive placebo matching to ZSP1273 orally once daily in the fasting state

ZSP1273(Food Effect)-Cohort 7

Drug:ZSP1273 /Placebo； Period 1 (Day1 to Day5): Subjects receive ZSP1273/Placebo under the fasting or fed condition ,respectively on Day1.

Period 2 (Day 8 to Day12): Subjects receive ZSP1273/Placebo under the fed or fasting condition, respectively on Day 8.

Group Type: EXPERIMENTAL

ZSP1273

Intervention Type: DRUG

ZSP1273 tablets administered orally once daily under fasted or fed condition

Placebo

Intervention Type: DRUG

Participants will receive placebo matching to ZSP1273 orally once daily under fasted or fed condition

ZSP1273(multiple doses)-Low Dose(Cohort 8)

while fasted or fed according to the results of Cohort FE

ZSP1273 /Placebo for 5 Days.

Group Type: EXPERIMENTAL

ZSP1273 Low Dose

Intervention Type: DRUG

ZSP1273 tablets administered orally once daily under fasted or fed condition for 5 Days.

Placebo

Intervention Type: DRUG

Participants will receive placebo matching to ZSP1273 orally once daily under fasted or fed condition for 5 Days.

ZSP1273(multiple doses)-Median Dose(Cohort 9)

while fasted or fed according to the results of Cohort FE

ZSP1273/Placebo for 5 Days.

Group Type: EXPERIMENTAL

ZSP1273 Median Dose

Intervention Type: DRUG

ZSP1273 tablets administered orally twice daily for 4 Days and once daily on Day 5 under fasted or fed condition.

Placebo

Intervention Type: DRUG

Participants will receive placebo matching to ZSP1273 orally twice daily for 4 Days and once daily on Day 5 under fasted or fed condition.

ZSP1273(multiple doses)-High Dose(Cohort 10)

while fasted or fed according to the results of Cohort FE

ZSP1273/Placebo for 5 Days.

Group Type: EXPERIMENTAL

ZSP1273 High Dose

Intervention Type: DRUG

ZSP1273 tablets administered orally twice daily for 4 Days and once daily on Day 5 under fasted or fed condition.

Placebo

Intervention Type: DRUG

Participants will receive placebo matching to ZSP1273 orally twice daily for 4 Days and once daily on Day 5 under fasted or fed condition.

Interventions

ZSP1273 100 mg

ZSP1273 tablet administered orally once daily under fasted condition

Intervention Type: DRUG

Placebo 100 mg

Participants will receive placebo matching to ZSP1273 orally once daily in the fasting state.

Intervention Type: DRUG

ZSP1273 200 mg

ZSP1273 tablets administered orally once daily under fasted condition

Intervention Type: DRUG

Placebo 200 mg

Participants will receive placebo matching to ZSP1273 orally once daily under fasted condition

Intervention Type: DRUG

ZSP1273 400 mg

ZSP1273 tablets administered orally once daily in the fasting state

Intervention Type: DRUG

Placebo 400 mg

Participants will receive placebo matching to ZSP1273 orally once daily in the fasting state

Intervention Type: DRUG

ZSP1273 600 mg

ZSP1273 tablets administered orally once daily under fasted condition

Intervention Type: DRUG

Placebo 600 mg

Participants will receive placebo matching to ZSP1273 orally once daily under fasted condition

Intervention Type: DRUG

ZSP1273 900 mg

ZSP1273 tablets administered orally once daily in the fasting state

Intervention Type: DRUG

Placebo 900 mg

Participants will receive placebo matching to ZSP1273 orally once daily under fasted condition

Intervention Type: DRUG

ZSP1273 1200 mg

ZSP1273 tablets administered orally once daily in the fasting state

Intervention Type: DRUG

Placebo 1200 mg

Participants will receive placebo matching to ZSP1273 orally once daily in the fasting state

Intervention Type: DRUG

ZSP1273

ZSP1273 tablets administered orally once daily under fasted or fed condition

Intervention Type: DRUG

Placebo

Participants will receive placebo matching to ZSP1273 orally once daily under fasted or fed condition

Intervention Type: DRUG

ZSP1273 Low Dose

ZSP1273 tablets administered orally once daily under fasted or fed condition for 5 Days.

Intervention Type: DRUG

Placebo

Participants will receive placebo matching to ZSP1273 orally once daily under fasted or fed condition for 5 Days.

Intervention Type: DRUG

ZSP1273 Median Dose

ZSP1273 tablets administered orally twice daily for 4 Days and once daily on Day 5 under fasted or fed condition.

Intervention Type: DRUG

Placebo

Participants will receive placebo matching to ZSP1273 orally twice daily for 4 Days and once daily on Day 5 under fasted or fed condition.

Intervention Type: DRUG

ZSP1273 High Dose

ZSP1273 tablets administered orally twice daily for 4 Days and once daily on Day 5 under fasted or fed condition.

Intervention Type: DRUG

Placebo

Participants will receive placebo matching to ZSP1273 orally twice daily for 4 Days and once daily on Day 5 under fasted or fed condition.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

Subjects are required to meet the following criteria in order to be included in the trial:

1. Signature of a dated Informed Consent Form (ICF) indicating that the subject has been informed of all the relevant aspects(including adverse events) of the trial prior to enrollment.

2. Subjects must be willing and able to adhere to the visit schedule and protocol requirements and be available to complete the study.

3. Subjects (including partners) must use reliable methods of contraception during the study and until 6 months following the last dose of investigational product.

4. Males and female subjects between 18-50 years (Both inclusive).

5. Body weight is no less than 50 kg in males and no less than 45 kg in females. Body mass index (BMI) 18≤BMI≤28 kg/m2; BMI is determined by the following equation: BMI = weight/height2 (kg/m2).

6. Physical condition and vital signs: Normal or abnormality has no clinical significance.

Exclusion Criteria

1. Known hypersensitivity and/or allergy to some drugs and food, especially for the composition that is similar to the investigative product;

2. The average daily smoking are more than 5 cigarettes within 3 months prior to screening.

3. Known history of drug or alcohol abuse.(defined as consumption of 14 units of alcohol per week: 1 unit = 285 ml of beer; or the equivalent of 25 ml of spirit, or 100 ml of wine )

4. Subjects who donated blood or bleeding profusely (> 400 mL) in the 3 months preceding study screening.

5. Dysphagia or any medical history in gastrointestinal that interferes with the absorption of drugs, include a history of frequent nausea or vomit causes by any etiology.

6. History or presence of any disease or condition known to increase the risk of bleeding , eg. acute gastritis, duodenal ulcer, etc.

7. Participant with any history of clinically significant skin disease such as, but not limited to, dermatitis, eczema, drug rash, psoriasis, or urticaria.

8. Subjects with recent significant change in diet or exercise.

9. Participated in another clinical research study and received any investigational products within 3 months prior to dosing.

10. Concomitant therapy with any drugs with known hepatic enzyme-inducing or inhibiting agents prior to screening or during the study, including strong inhibitory agents and inducers that affect metabolic enzymes (see appendix 6 for specific drug information).

11. Use of any prescription or over-the-counter (OTC) medications, vitamins and herbal or dietary supplements within 14 days prior to screening.

12. History of having any special food (including dragon fruit, mango, grapefruit, etc.), strenuous exercises, or other factors may interfere with the absorption, distribution, metabolism, or excretion of drug within 14 days prior to screening.

13. Inability to consume the food provided in the study ( a high fat, high calorie meal includes two eggs , a piece of butter bacon toast, a box of fried potatoes, and a glass of whole milk).This requirement only applies to subjects under fed condition.

14. Presence of clinically significant abnormalities in ECG or QTcB>470ms in males, or QTcB>480ms in females.

15. Pregnancy or breastfeeding at screening and during the study. All female subjects of childbearing potential must have a negative urine pregnancy test at screening and during the trial.

16. Any clinically significant abnormality upon physical examination or presence of a clinically significant gastrointestinal, renal, hepatic, neurologic, hematic, endocrine, neoplastic, pulmonary, immune, psychiatric or cardiovascular and cerebrovascular disorder(s)(but not limited to above disorders) in the 6 months preceding study screening.

17. Positive hepatitis B surface antigen, hepatitis C virus antibody,human immunodeficiency virus (HIV) or treponema pallidum antibodies at screening.

18. Any acute illness or concomitant medication from screening to first dosing.

19. Have chocolate, any food or beverage that contains caffeine or xanthine within 24 hours prior to dosing.

20. Positive for urine drug screening or history of substance and drug abuse for a period of 5 consecutive years before screening.

21. Subjects who may not complete the study for other reasons or should not be included in the study in the opinion of the investigator.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 50 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Guangdong Zhongsheng Pharmaceutical Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Yanhua Ding, MD

Role: PRINCIPAL_INVESTIGATOR

The First Hospital of Jilin University

Shucheng Hua, MD

Role: PRINCIPAL_INVESTIGATOR

The First Hospital of Jilin University

Locations

The First Hospital of Jilin University

Changchun, Jilin, China

Countries

China

References

Hu Y, Li H, Wu M, Zhang H, Ding Y, Peng Y, Li X, Yu Z. Single and multiple dose pharmacokinetics and safety of ZSP1273, an RNA polymerase PB2 protein inhibitor of the influenza A virus: a phase 1 double-blind study in healthy subjects. Expert Opin Investig Drugs. 2021 Nov;30(11):1159-1167. doi: 10.1080/13543784.2021.1994944. Epub 2021 Nov 1.

Reference Type: DERIVED

PMID: 34654349 (View on PubMed)

Other Identifiers

ZSP1273-18-01

Identifier Type: -

Identifier Source: org_study_id